Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.
When it comes to manoeuvrability and nimble response, large companies have more in common with ocean liners than speedboats. Policies are agreed, marketing strategies planned, and future developments or projects set in motion months or years in advance. Full Article »
Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.
Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells, leading to major side effects such as loss of hair, nausea and vomiting, and risk of infection. Survival was sometimes better, but not much better, depending on the type of cancer and the patient's own genetic and physiological make-up. The big advantage of IO therapies is that they can target specific receptors on the cancer cells and destroy them while leaving the healthy cells alone. This will also help reduce some of the traditional side effects when healthy cells are destroyed. Full Column »
Many life sciences companies are guilty of overlooking the impact of impersonal one-size-fits all email campaigns. Full Whitepaper »